Blog

Polydispersity of Polymer Carriers

The polymers in this context are a polymeric linear structures with n repeating units of monomers. Depending whether the polymer is consisting of one single molecular weight (only one n existing) or of a range of compounds with an average mass and a distribution of n around a mean value, polymers are referred to as “monodisperse” or “polydisperse”.

Comparison of Carriers for Polymer Therapeutics

The polymers in this context are a polymeric linear structures with n repeating units of monomers. Depending whether the polymer is consisting of one single molecular weight (only one n existing) or of a range of compounds with an average mass and a distribution of n around a mean value, polymers are referred to as “monodisperse” or “polydisperse”.

Poly(Glutamic Acid) as Versatile Biodegradable Drug Carrier

Polyglutamates are well known to be highly biocompatible, biodegradable and multifunctional polymers, which have already been used as building blocks in polymer drug conjugates and polymeric micelles.

Polysarcosine – a True Alternative to PEG

Potential alternatives to PEGs, polypeptoids in general and polysarcosine (PSR) in particular stand out in terms of safety, synthetic control and versatility.

Poly(Ethylene Glycol) – the Pioneer in Polymer Therapeutics

PEGs show a spectrum of unique physical and chemical properties, which have been described in literature extensively by the pioneers in PEGylation: Harris, Veronese and recently by Hermanson. Here are summarized the most common known properties.

Amino-PEG-Acids and their Active Esters

Amino protected amino-PEG-acids can be used for the PEGylation of solid particles in order to create hydrophilic and reactive surfaces with no non-specific binding issues.

Lipoamide-PEGs Confer Extra Strong Binding

Nanotechnology and nanobiotechnology using gold or silver particles, quantum dots or even magnetic particles are broadly diverse, rapidly expanding areas of study in medical diagnostics and therapeutics, sensoric and chemistry.

Polymers Enlarge the Potential of Biopharmaceuticals

The Biopharmaceuticals market, estimated at US$ 200 billion globally in 2013 by reportbuyer.com (Biopharmaceuticals - A Global Market Overview, 2013, London), is further projected to reach US$ 500 billion by 2020, growing at 13.5 % CAGR between 2010 and 2020.

Pharmacological Effects of Polymer Therapeutics

Small drug molecules and also large biomolecules like proteins or antibodies suffer rapid clearance from human body.

A Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Model for Predicting the Enantioselectivity of Candida antarctica Lipase B